The company has demonstrably advanced the progress of the innovative solution for ATTR-CM, utilizing the investigational drug. Initial patient information indicates promising outcomes for individuals affected by a https://bridgebio238417.livebloggs.com/48922404/bridgebio-advances-amyloidosis-treatment-through-the-drug